论文部分内容阅读
目的:探讨经尿道钬激光前列腺剜除术(HoLEP)术后尿失禁的临床特征和危险因素。方法:回顾性分析2016年1月至2018年12月本院收治的375例良性前列腺增生行HoLEP治疗患者的临床和随访资料，总结术后尿失禁的发生率、类型、严重程度和恢复情况，分析影响术后尿失禁的相关因素。结果:本组HoLEP术后尿失禁总体发生率为16.5%(62/375)，其中压力性、急迫性和混合性尿失禁分别为8.0%(30/375)、6.1%(23/375)和2.4%(9/375)；轻度占74.2%(46/62)、中度占19.4%(12/62)、重度占6.4%(4/62)；96.8%(60/62)尿失禁症状在术后3个月内消失。单因素分析结果显示，HoLEP术后尿失禁与患者年龄(n χ2＝6.510，n P＝0.011)、糖尿病(n χ2＝6.074，n P＝0.014)、术前前列腺体积(n χ2＝12.008，n P＝0.001)、手术时间(n χ2＝31.753，n P100 mL(n OR＝1.87，95%n CI：1.15～3.69，n P＝0.021)是术后尿失禁发生的独立危险因素。n 结论:HoLEP术后尿失禁以轻度为主，呈现短暂性、自限性的特点，手术应激是导致术后尿失禁的主要危险因素。“,”Objective:To investigate the clinical characteristics and risk factors of urinary incontinence after transurethral holmium laser enucleation of the prostate(HoLEP).Methods:From January 2016 to December 2018, clinical data of 375 patients with benign prostatic hyperplasia who were treated with HoLEP were retrospectively analyzed. The incidence, type, severity and recovery of postoperative urinary incontinence were summarized.Univariate and multivariate logistic regression analysis was used to analyze the related factors of postoperative urinary incontinence.Results:The overall incidence of urinary incontinence after HoLEP was 16.5%(62/375). The incidence of stress, urgency and mixed urinary incontinence was 8.0%(30/375), 6.1%(23/375) and 2.4% (9/375), respectively.Mild, moderate and severe urinary incontinence accounted for 74.2%(46/62), 19.4%(12/62) and 6.4%(4/62), respectively, and 96.8%(60/62) of urinary incontinence recovered within 3 months after operation. Univariate analysis showed that urinary incontinence after HoLEP was correlated with age(n χ2=6.510, n P=0.011), diabetes mellitus(n χ2=6.074, n P=0.014), preoperative prostate volume(n χ2=12.008, n P=0.001), operation time(n χ2=31.753, n P100 mL(n OR=1.87, 95%n CI: 1.15-3.69, n P=0.021) were independent risk factor for postoperative urinary incontinence.n Conclusions:Urinary incontinence after HoLEP is mainly mild, with the characteristics of transient and self-limiting.Surgical stress is the main risk factor for urinary incontinence after HoLEP.